指南与共识脊柱关节炎

EULAR银屑病关节炎药物治疗管理建议:2019年更新

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
指南 / 共识 · Ann Rheum Dis · 2020-01-01

该更新基于系统文献综述和2019年5月28名国际专家共识会议,提出6条总体原则和12条推荐。推荐涵盖从NSAIDs/局部糖皮质激素初始治疗到csDMARDs、bDMARDs(靶向TNF、IL-17A或IL-12/23)及JAK抑制剂的阶梯策略,并涉及药物转换和持续缓解减量。

要点

  • 初始治疗推荐NSAIDs和局部糖皮质激素注射。
  • 关节炎伴不良预后因素者应快速启动csDMARDs。
  • csDMARDs未达标者启动靶向TNF、IL-17A或IL-12/23的bDMARDs。

核心结论

  • 基于证据与专家意见结合,为PsA药物治疗提供更新共识推荐。

研究设计与样本

  • 按EULAR标准化操作流程,系统文献综述后于2019年5月召开28名国际工作组成员共识会议制定。

主要发现

  • 更新推荐包含6条总体原则和12条推荐,涉及肌肉骨骼和非肌肉骨骼表现及协同管理。

关键数值与推荐

  • 初始治疗 proposed 为非甾体抗炎药和局部糖皮质激素注射。
  • 关节炎伴多关节炎或寡关节炎/单关节炎合并指炎或关节损伤等不良预后因素时,推荐快速启动csDMARDs。
  • csDMARDs策略未达标时,启动靶向TNF、IL-17A或IL-12/23的bDMARDs,需考虑皮肤受累。
  • 中轴病变为主时,一线DMARD推荐TNF抑制剂或IL-17A抑制剂。
  • JAK抑制剂主要推荐用于bDMARDs失败后;磷酸二酯酶-4抑制用于其他药物不适用者,通常为轻症。

临床怎么用

  • 按推荐阶梯选择药物,评估关节炎表现、不良预后因素、皮肤及中轴受累。
  • 持续缓解时考虑药物转换和减量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA). METHODS: According to the EULAR standardised operating procedures, a systematic literature review was followed by a consensus meeting to develop this update involving 28 international taskforce members in May 2019. Levels of evidence and strengths of recommendations were determined. RESULTS: The updated recommendations comprise 6 overarching principles and 12 recommendations. The overarching principles address the nature of PsA and diversity of both musculoskeletal and non-musculoskeletal manifestations; the need for collaborative management and shared decision-making is highlighted. The recommendations provide a treatment strategy for pharmacological therapies. Non-steroidal anti-inflammatory drugs and local glucocorticoid injections are proposed as initial therapy; for patients with arthritis and poor prognostic factors, such as polyarthritis or monoarthritis/oligoarthritis accompanied by factors such as dactylitis or joint damage, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is recommended. If the treatment target is not achieved with this strategy, a biological disease-modifying antirheumatic drugs (bDMARDs) targeting tumour necrosis factor (TNF), interleukin (IL)-17A or IL-12/23 should be initiated, taking into account skin involvement if relevant. If axial disease predominates, a TNF inhibitor or IL-17A inhibitor should be started as first-line disease-modifying antirheumatic drug. Use of Janus kinase inhibitors is addressed primarily after bDMARD failure. Phosphodiesterase-4 inhibition is proposed for patients in whom these other drugs are inappropriate, generally in the context of mild disease. Drug switches and tapering in sustained remission are addressed. CONCLUSION: These recommendations provide stakeholders with an updated consensus on the pharmacological management of PsA, based on a combination of evidence and expert opinion.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020. PMID: 32434812. doi:10.1136/annrheumdis-2020-217159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。